Rectal neoplasm

This trial tests a new way to treat rectal cancer without surgery. People with localized rectal cancer who cannot have or refuse surgery will receive external beam radiation followed by a high-dose internal radiation boost, using a 3D-printed guide and tungsten shielding to prote…

This phase 2 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can completely eliminate early-stage rectal cancer in people whose tumors are microsatellite stable (MSS). Participants receive one infusion of botensilimab followed by b…

This trial is testing a combination of local tumor removal and chemoradiotherapy (radiation plus capecitabine chemotherapy) in people with early-stage rectal cancer located low in the rectum. The goal is to see if this approach can effectively treat the cancer while avoiding the …

This trial is testing whether adding two immunotherapy drugs—zimberelimab and etrumadenant—to standard chemotherapy and a short course of radiation can completely eliminate rectal cancer. Adults with locally advanced rectal cancer that has not spread will receive the treatment, a…

This phase 2 trial is testing whether adding an immunotherapy drug (adebrelimab) to a chemotherapy combo (NALIRIFOX) and radiation can improve outcomes for people with a certain type of locally advanced rectal cancer (pMMR/MSS). About 84 participants will be randomly assigned to …

This study tests an experimental oral drug, GSK5460025, alone or with other cancer drugs, in adults whose solid tumors have specific genetic changes (dMMR or MSI-H). The goal is to see if the drug can shrink tumors and to check its safety. About 47 people with advanced cancers th…

This study is testing whether the immunotherapy drug dostarlimab (TSR-042), followed by standard chemoradiation and surgery, can effectively treat advanced mismatch repair deficient (dMMR) solid tumors. About 212 adults with locally advanced dMMR cancers will receive the drug int…

This trial is investigating whether it is safe to skip the removal of a specific group of lymph nodes (the No.253 lymph nodes) during surgery for mid and low rectal cancer. The standard surgery removes these nodes, but this study compares the long-term survival of patients who ha…

Researchers are testing whether a combination of two drugs, atezolizumab and bevacizumab, can clear tiny amounts of cancer DNA from the blood of people whose gastrointestinal cancer was treated with curative intent. The trial enrolls 20 adults with colon, rectal, gastric, pancrea…

This phase 3 trial is testing whether adding the targeted drugs calderasib and cetuximab to standard chemotherapy can help people with a specific gene mutation (KRAS G12C) in advanced colorectal cancer live longer without their cancer growing. About 477 participants will receive …

This study tests whether giving radiation before surgery lowers the chance of rectal cancer returning in the same area. Researchers will follow 100 people with locally advanced proximal rectal cancer who receive either radiation followed by surgery or surgery alone. The main goal…

This study is for people with rectal cancer that didn't fully go away after standard chemotherapy and radiation. Researchers want to see if giving a few extra doses of internal radiation (brachytherapy) can finish off the tumor and let patients keep their rectum instead of needin…

This study is for people with locally advanced rectal cancer. It tests whether using MRI scans early after chemotherapy can help doctors choose the best next step: surgery or more chemo with radiation. The goal is to improve cancer control and reduce side effects. About 1,075 par…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This study is testing a new surgical stapler, called the Signia circular stapler, in people having left-sided colon, sigmoid, or rectal surgery. The goal is to see if it lowers the chance of a leak where the colon is reconnected. About 137 adults will take part, and the main focu…

This trial tests whether giving chemotherapy after chemoradiation but before surgery improves outcomes for people with locally advanced rectal cancer. Participants are randomly assigned to either the standard approach (chemoradiation, then surgery, then chemotherapy) or the exper…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This trial compares two standard bowel preparation methods—Fleet enema (given rectally) and Pico-Salax (taken orally)—to see which cleans the rectum better before transanal endoscopic surgery. The study includes adults undergoing this surgery at a single center, and measures clea…

This study tests a device called ColoSeal ICD, placed during rectal cancer surgery to protect the bowel connection and reduce the need for a stoma (a bag on the belly for waste). About 250 adults aged 22-75 with rectal cancer will be split into two groups: one gets the device, th…

This phase 2 trial is testing whether an investigational drug called BMX-001 can reduce severe side effects from radiation therapy in people with newly diagnosed locally advanced rectal cancer. Participants will receive either short or long course radiation therapy, with or witho…

This trial is testing whether proton beam radiation, a more precise form of radiation, causes fewer stomach and bowel side effects than standard photon radiation when given before surgery for high-risk rectal cancer. About 254 patients will be randomly assigned to receive either …

This trial tests whether a combination of contact X-ray brachytherapy and short-course radiotherapy can preserve the rectum in people with early-stage rectal cancer. Participants receive this experimental radiation regimen, with some also getting chemotherapy. The goal is to see …

This phase 2 trial tests a new approach for patients with a specific type of mid-low rectal cancer (pMMR/MSS). Participants receive a short course of radiation followed by six cycles of the immunotherapy drug ivonescimab. The goal is to see if this combination can make the cancer…

This study compares two standard treatment approaches for older adults (age 70+) with locally advanced rectal cancer. The goal is to see which approach helps people live longer and with fewer side effects. About 230 participants will be randomly assigned to receive either convent…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This trial compares two treatments for people with early-stage (T2) rectal cancer located near the anus. One group receives a less invasive procedure called transanal local excision followed by radiotherapy, while the other group undergoes standard major surgery (total mesorectal…

This phase 2 trial tests whether adding a new form of chemotherapy (liposomal irinotecan) to standard radiotherapy, immunotherapy (tislelizumab), and another chemotherapy (capecitabine) can make advanced rectal cancers disappear before surgery. The study enrolls adults aged 18–75…

This early-stage trial tests whether adding the drug papaverine to standard radiation therapy can safely improve treatment for locally advanced rectal cancer. Papaverine may help by reducing oxygen starvation inside tumors, which often makes radiation less effective. The study en…

This phase 2 trial will test whether adding immunotherapy drugs (cemiplimab alone or with fianlimab or REGN7075) to standard chemotherapy (capecitabine and oxaliplatin) can completely eliminate tumors in patients with locally advanced rectal cancer before surgery. The study plans…

This study tests whether giving chemotherapy alone before limited surgery works as well as chemotherapy plus radiation for early rectal cancer. The goal is to see if avoiding radiation improves quality of life without harming cancer control. About 250 adults with early-stage rect…

This phase I trial tests a modified vaccinia virus (BT-001) injected directly into rectal tumors, followed by a single dose of the immunotherapy drug pembrolizumab. The study enrolls about 20 adults with localized pMMR rectal cancer who are candidates for surgery. The main goal i…

This trial tests a temporary bypass device called CG-100 in 250 rectal cancer patients undergoing surgery. The device is placed inside the bowel to protect the surgical connection, potentially reducing the need for a temporary stoma. Researchers will compare stoma rates and compl…

This phase 2 trial is testing a two-month course of chemotherapy (mFOLFOX) followed by short-course radiation before surgery for people with resectable rectal cancer. The goal is to see if this approach improves the chance of being cancer-free three years later. About 54 particip…

This Phase 3 trial tests whether adding immunotherapy and a targeted drug to short-course radiotherapy and chemotherapy improves outcomes for people with high-risk rectal cancer. About 204 participants will receive either the standard treatment or the intensified combo. The study…

This study tests whether giving two immunotherapy drugs (botensilimab and balstilimab) before surgery can shrink tumors and improve outcomes for people with advanced colon cancer that can be removed. About 100 adults with stage IIB to IIIC colorectal cancer will receive the drugs…

This study tests two ways of giving extra radiation after standard chemoradiation to people with early-stage rectal cancer. The goal is to see which method helps more people achieve a complete response, so they can avoid major surgery and keep their rectum. About 131 participants…

This phase II trial tests whether giving a combination of chemotherapy (FOLFOX) and two immunotherapy drugs (botensilimab and balstilimab) before surgery can eliminate rectal cancer without the need for surgery or radiation. The study includes adults with stage II or III rectal c…

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

This trial tests whether close follow-up (active surveillance) is as good as chemoradiotherapy for preventing cancer return after early-stage rectal cancer removal. About 480 adults with intermediate-risk T1 rectal cancer will be randomly assigned to either regular checkups and s…

This phase I trial tests a surgical procedure called utero-ovarian transposition (UOT) to temporarily move the uterus, ovaries, and fallopian tubes out of the radiation field in women aged 18-40 with pelvic cancers. The goal is to preserve fertility and ovarian function during wh…

This study compares a new treatment approach for high-risk rectal cancer: short-course radiation followed by immunotherapy (toripalimab) and chemotherapy (FOLFOX) versus the standard long-course chemoradiation. The goal is to see if the new approach leads to more complete tumor r…

This study is testing whether active surveillance (watchful waiting) is as safe as surgery for people with low rectal cancer who have a complete response after chemoradiotherapy. About 90 participants will be monitored for 2 years to see how often the cancer returns and whether d…

This study tests whether using a special reinforcing material (SIS) during bowel reconnection after rectal cancer surgery can prevent dangerous leaks. About 966 adults with mid-to-low rectal cancer will be randomly assigned to receive either the reinforced connection or the stand…

This study tests whether a lower dose of short-course radiotherapy, combined with chemotherapy and two immune-boosting drugs, works as well as the standard radiation dose for locally advanced rectal cancer. About 122 adults will be randomly assigned to one of two radiation doses,…

This study compares two modern surgical techniques for removing low rectal cancer: transanal total mesorectal excision (taTME) and robot-assisted total mesorectal excision (RTME). Researchers want to see which method leads to fewer complications and less need to switch to open su…

This study tests a combination of two drugs (fruquintinib and FOLFIRI) in people with advanced colorectal cancer that has spread. It is for those who have already had one prior treatment. The goal is to see if this new combination can help control the cancer longer and with manag…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …

This study compares two common surgical procedures—loop ileostomy and loop colostomy—used as protective stomas after rectal cancer surgery. Researchers want to see which one leads to fewer stoma-related problems within the first 60 days. About 350 patients will be randomly assign…

This study looks at whether giving FOLFIRINOX chemotherapy before surgery helps people with mid or lower rectal cancer that has spread to the liver. The goal is to see if both the rectal tumor and liver spots can be completely removed. About 550 adults will take part, and the mai…

This study tests whether giving chemotherapy after surgery can prevent rectal cancer from returning in people who have a positive ctDNA blood test (a sign of leftover cancer cells). About 103 adults with high-risk rectal cancer will either receive chemo or be observed. The goal i…

This study tests whether giving a higher radiation dose to the tumor can help people with early-stage rectal cancer keep their rectum instead of needing surgery. About 25 adults will receive targeted radiation using a special adaptive technique. The goal is to see if this approac…

This study tests whether giving a strong chemotherapy directly to the liver, followed by standard cancer pills and an injection, works better than the standard treatment alone. It is for people whose colorectal cancer has spread mostly to the liver and is no longer responding to …

This study tests whether adding a citrus flavonoid tablet (Aimailang) to standard chemotherapy (mFOLFOX) before surgery can shrink tumors more effectively in people with locally advanced rectal cancer that has a specific marker (YWHAB). About 236 participants will be randomly ass…

This study looks at whether giving a drug called somatostatin along with a clear liquid diet for a week after rectal cancer surgery can prevent dangerous bowel leaks as well as a temporary stoma (a bag outside the body). About 72 adults with low or mid rectal cancer will be rando…

This early-phase trial is testing whether people with stage II-III rectal cancer can safely avoid surgery by first receiving chemotherapy and then being closely monitored. The goal is to see if the rectum can be preserved without harming survival. Around 120 participants will be …

This study tests whether adding an immunotherapy drug (sintilimab) to short-course radiation and chemotherapy can improve long-term survival in people with a common type of locally advanced rectal cancer (MSS type). About 130 adults aged 18-75 with stage II/III rectal cancer will…

This Phase II trial tests whether adding a dual immunotherapy drug (iparomlimab/tuvonralimab) to standard chemoradiotherapy can improve outcomes for patients with locally advanced rectal cancer that has a specific genetic profile (pMMR/MSS), which usually does not respond to immu…

This phase 3 trial tests whether adding an immunotherapy drug (HLX10) to standard chemotherapy and radiation before surgery improves outcomes for people with locally advanced rectal cancer. It compares short-course versus long-course radiation, both followed by immunotherapy and …

This study tests whether low-risk rectal cancer patients can safely undergo surgery without a temporary stoma (a bag attached to the belly to collect waste). The trial will compare leak rates in 442 patients who either get a stoma or not. If skipping the stoma is shown to be safe…

This phase 2 trial tests whether adding two targeted drugs (tucatinib and trastuzumab) to standard chemotherapy can shrink HER2-positive rectal tumors before surgery. About 37 adults with locally advanced rectal cancer will receive the drug combo for 6 weeks, then continue it wit…

This study tests whether a combination of chemotherapy and radiation (total neoadjuvant therapy, or TNT) can shrink rectal tumors enough so that some patients can avoid surgery and instead be monitored closely. About 400 adults with early-stage rectal cancer will be randomly assi…

This study tests whether taking sildenafil (a drug for erectile dysfunction) daily for 10 months, starting 30 days after surgery, can prevent long-term erectile problems in men treated for rectal cancer with radiation and surgery. The trial includes 188 men aged 18 to 70 who had …

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a treatment plan for people with low rectal cancer that can be removed with surgery. Participants receive chemotherapy and an immunotherapy drug called tislelizumab before surgery. The goal is to see if this combination can make the cancer disappear completely, a…

This phase 3 trial is testing whether adding the immunotherapy drug pucotenlimab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced rectal cancer. About 556 participants will be randomly assigned to receive either CAPOX plus puco…

This study tests whether patients with a specific type of rectal cancer (dMMR/MSI-H) can safely avoid surgery after immunotherapy. After six rounds of a PD-1 inhibitor, those whose tumors completely disappear will be monitored closely instead of undergoing standard treatments. Th…

This study tests whether adding a short course of radiation to a mix of immunotherapy (iparomlimab and tuvonralimab), a targeted drug (regorafenib), and chemotherapy (CAPOX) can better shrink advanced rectal cancer before surgery. About 88 adults with a specific type of rectal ca…

This phase 3 trial compares two different oral chemotherapy drugs given alongside radiation before surgery for locally advanced rectal cancer. The standard drug, capecitabine, is being tested against a newer drug called TAS-102. The goal is to see if TAS-102 leads to more tumors …

This phase 2 trial is testing a new approach for people with a certain type of locally advanced rectal cancer. The treatment combines short-course radiation (sparing lymph nodes), two chemotherapy drugs (capecitabine and oxaliplatin), and an immunotherapy drug (sintilimab). The g…

This phase 2 trial is testing whether adding a dietary supplement called β-hydroxybutyrate to a standard treatment plan (short-course radiotherapy, immunotherapy, and chemotherapy) can improve outcomes for people with locally advanced rectal cancer. The study will enroll 25 adult…

This phase II trial tests whether giving zanidatamab before surgery can shrink tumors in people with HER2+ colorectal cancer. About 38 participants will receive the drug intravenously, then undergo surgery. The study measures how much the tumor regresses and whether cancer return…

This study tests whether putting a person's own intestinal fluid back into their stoma can prevent a common and distressing bowel condition called Low Anterior Resection Syndrome (LARS) after rectal cancer surgery. 160 participants will either receive their own intestinal fluid o…

This phase 2 trial is testing whether adding the antibiotic metronidazole to standard therapy can reduce harmful bacteria (F. nucleatum) in rectal cancer patients. About 60 adults with locally advanced rectal cancer will receive either standard treatment plus metronidazole or sta…

This phase 2 study tests a total neoadjuvant therapy approach for stage II or III rectal cancer. Participants receive short-course radiotherapy followed by 9 cycles of mFOLFOX6 chemotherapy before any surgery. The goal is to see how many patients achieve a complete response, mean…

This study tests whether adding a targeted drug (surufatinib) to a standard pre-surgery regimen of short-course radiation, chemotherapy, and immunotherapy (toripalimab) can improve outcomes for people with high-risk mid-to-low rectal cancer. About 212 participants will receive on…

This early-phase trial tests whether a short course of radiation followed by chemotherapy can shrink advanced rectal tumors enough to avoid surgery. About 25 people with stage II or III rectal cancer will receive the treatment. The goal is to preserve the rectum and improve quali…

This study tests whether a special delayed-connection surgery (Turnbull-Cutait) can help people with low rectal cancer avoid a permanent colostomy bag better than the standard surgery with a temporary stoma. About 520 adults aged 18-75 with rectal cancer will be randomly assigned…

This study tests a new way of giving three chemotherapy drugs (TAS-102, oxaliplatin, and irinotecan) along with bevacizumab to people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this approach can control the cancer and…

This early-phase trial tests whether MRI-guided adaptive radiation therapy, combined with the chemotherapy drug capecitabine, can safely treat rectal cancer while preserving the rectum. About 22 adults with stage I-III rectal cancer will receive escalating doses of radiation guid…

This study tests a new treatment plan for people with high-risk rectal cancer that hasn't spread. Patients get a short course of radiation, then a mix of chemotherapy and immunotherapy before considering surgery. If the cancer disappears completely, patients may choose a 'watch a…

This phase 2 trial is testing whether adding a probiotic called Probio-M9 to standard chemoradiation and an immunotherapy drug (tislelizumab) can improve outcomes for people with locally advanced rectal cancer. About 50 participants will be randomly assigned to receive either the…

This study is for people with a certain type of locally advanced rectal cancer (pMMR/MSS) that often doesn't respond well to immunotherapy alone. The trial combines an immunotherapy drug (serplulimab) with chemotherapy (CAPEOX) and an anti-inflammatory drug (celecoxib) to see if …

This phase 2 trial tests whether giving a combination of chemotherapy (oxaliplatin and capecitabine) and the immunotherapy drug tislelizumab before surgery can shrink or eliminate tumors in people with locally advanced rectal cancer. About 35 participants will receive three cycle…

This study tests a personalized, stage-based approach to treat rectal cancer while trying to avoid removing the rectum. 200 participants will receive either experimental chemoradiotherapy or minimally invasive surgery depending on their cancer stage. The goal is to preserve the r…

This phase 3 trial is testing whether a powerful chemotherapy combination (mFOLFOXIRI plus bevacizumab) can be used instead of standard chemoradiation before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can reduce the chanc…

This study tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy can shrink advanced bile duct tumors enough for surgery. About 20 adults with locally advanced, inoperable bile duct cancer will receive the combination treatment. The main goal is to see h…

This study tests a combination of three drugs (trastuzumab-deruxtecan, capecitabine, and bevacizumab) as a first treatment for people with HER-2 positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see how well the drugs shrink tumors. About …

This study tests whether a special MRI-guided radiation machine (MR-linac) can deliver high-dose radiation precisely to rectal tumors, allowing patients to avoid surgical removal of the rectum. About 100 people with early-stage rectal cancer will receive this radiation along with…

This study tests whether adding the drug epacadostat to standard chemoradiation helps treat locally advanced rectal cancer before surgery. About 49 adults with stage 2 or 3 rectal cancer will receive short-course radiation, chemotherapy, and epacadostat. The goal is to find the b…

This study tests whether two drugs, botensilimab and balstilimab, can clear remaining cancer DNA in people with colorectal cancer who still have signs of disease after standard treatments like surgery and chemotherapy. About 284 adults with a specific type of colorectal cancer (M…

This study compares giving chemotherapy before surgery versus after surgery for people with locally advanced rectal cancer who have a low risk of the cancer coming back in the same area. The goal is to see which timing helps patients live longer without the cancer returning. Abou…

This study tests whether placing live probiotic tablets into the unused part of the gut during a temporary ileostomy can improve bowel function after the stoma is reversed. 156 adults with ultra-low rectal cancer who had sphincter-saving surgery will be randomly assigned to a low…

This phase 3 trial tests whether adding modulated electro-hyperthermia (mEHT) to standard treatment helps shrink locally advanced rectal cancer. About 126 adults will receive either standard therapy alone or with mEHT twice a week for six weeks. The goal is to see if the heat-bas…

This study is testing whether adding leucine, a common amino acid found in food, to standard chemoradiotherapy can help shrink tumors more effectively in people with locally advanced rectal cancer. The researchers believe leucine may interfere with cancer cells' ability to repair…

This study tests whether using chemotherapy alone before surgery works as well as chemotherapy followed by radiation for people with locally advanced rectal cancer. About 540 adults with stage T3 or node-positive rectal cancer will take part. The goal is to see if avoiding radiat…

This phase 2 trial is testing a new approach for patients with a specific type of locally advanced rectal cancer (MSS-type). Participants will receive a short course of radiation, followed by chemotherapy combined with two additional drugs: serplulimab (an immunotherapy) and beva…

This phase 3 trial compares standard versus higher-dose radiotherapy, combined with chemotherapy, in 162 people with early low or mid rectal cancer. The goal is to see if a higher dose helps more patients achieve a complete response and avoid surgery, preserving their rectum. Par…

This phase 2 trial tests a new treatment for early-stage rectal cancer that has not spread to lymph nodes. Instead of radiating the whole pelvis, doctors give a short course of radiation only to the tumor, followed by chemotherapy and an immunotherapy drug. The goal is to shrink …

This phase 2 trial compares two types of radiotherapy (short-course vs long-course) given alongside immunotherapy (Adebrelimab) and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see which approach leads to a higher rate of complete tumor disappear…

This early-phase study tests whether giving extra, MRI-guided radiation after standard treatment is safe and effective for people with rectal cancer. About 37 participants will first receive standard chemoradiation, then get additional radiation that adjusts every two weeks based…

This study tests whether adding a special medical food that restricts certain amino acids (NEAAR) to standard cancer therapy (radiation and chemotherapy) is safe and tolerable for people with locally advanced rectal cancer. About 30 adults will participate. The goal is to see if …

This study is testing whether people with early- or intermediate-stage low rectal cancer can safely avoid major surgery if their tumor responds well to chemotherapy and radiation. Instead of removing the rectum, doctors will closely monitor patients using a "watch-and-wait" appro…

This study tests a new step before rectal cancer surgery: temporarily blocking the main artery to the lower colon with a tiny coil. The idea is to 'precondition' the tissue so it handles surgery better, potentially reducing leaks and other complications. 30 patients with rectal c…

This early-stage study is testing a new treatment called CEA-targeted CAR-T cells for people with advanced solid tumors like lung, stomach, colon, rectal, esophageal, or pancreatic cancer that have not responded to standard therapies. The treatment uses a patient's own immune cel…

This study is for people with locally advanced rectal cancer that hasn't spread. It tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation plus chemotherapy and targeted therapy) can lead to a complete disappearance of the…

This study tests A2B395, a donor-derived CAR T-cell therapy designed to target cancer cells while sparing healthy ones. It is for adults with advanced solid tumors like colorectal, lung, or breast cancer that have lost a specific immune marker. The trial has two phases: first to …

This study tests whether adding the immunotherapy drug pucotenlimab to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer. About 68 participants will receive the combination, and doctors will check if the tumor disappears completely. If it…

This study is testing whether people with rectal cancer who have a complete response to initial therapy can safely avoid surgery and instead be closely monitored. Researchers will track 200 participants to see how often the cancer stays away or comes back. The goal is to preserve…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

This study is developing a blood test that uses tiny particles called exosomes and machine learning to detect colorectal cancer in people under 50. The test looks for specific microRNA patterns in the blood. Researchers will compare results from 400 people—some with cancer and so…

This study is testing whether a new type of CT scanner, called photon-counting detector CT (PCD-CT), can determine how far rectal cancer has grown as accurately as MRI. About 200 adults with rectal cancer will get both a standard MRI and the new CT scan, and doctors will compare …

This study is testing a smartphone app that lets rectal cancer patients log their bowel symptoms daily. The goal is to create a better tool for doctors to understand and manage these symptoms. About 158 participants who had rectal surgery or are on a watch-and-wait plan will use …

This study tests whether a stool DNA test (mt-sDNA) can accurately detect polyps or cancer in people who have already been treated for stage I-III colorectal cancer. Researchers will compare the stool test results to colonoscopy findings in 50 survivors. The goal is to see if the…

This study is testing a new device that combines ultrasound with photoacoustic imaging to look at rectal tumors. The goal is to see if it can more accurately tell whether a patient's cancer has completely responded to pre-surgery treatment. If it works, doctors could avoid operat…

This early study tests a special PET/CT scan that uses a modified tryptophan molecule to make tumors light up more clearly than normal tissue. About 24 adults with brain, breast, neuroendocrine, or rectal cancers will get one scan to see if this method helps doctors tell tumors a…

This study is testing a new type of PET scan that uses special probes to highlight digestive system cancers, such as stomach, liver, colon, and pancreatic cancers. Researchers will enroll 400 adults to see how well this imaging method finds tumors and tracks their response to tre…

This study looks at whether people who have had 1 or 2 small, non-cancerous polyps removed can safely wait 10 years for their next colonoscopy instead of the usual 5 years. About 9,500 adults aged 45-69 will be randomly assigned to one of two schedules: a colonoscopy at 5 and 10 …

This study is testing whether rinsing the rectal cavity with a saltwater or iodine solution during laparoscopic surgery can prevent local recurrence of mid-to-low rectal cancer. About 1,600 patients will be randomly assigned to receive the wash or not, and they will be followed f…

This study tests whether a special algorithm called PAGODA can reduce unplanned delays during FOLFOX chemotherapy for gastrointestinal cancers like colon, stomach, and esophageal cancer. About 420 participants will be randomly assigned to either standard care or the algorithm-gui…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This trial tests whether adding aerobic exercise and guided imagery to standard care can reduce bowel symptoms and improve quality of life in people with low anterior resection syndrome (LARS) after rectal cancer surgery. Participants will be randomly assigned to either the exerc…

This study tests whether a small nerve stimulator placed on the skin near the ankle can help people who have bowel leakage after rectal cancer surgery. Half of the 84 participants will use the active device at home, while the other half will use a sham device. Researchers will ch…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests whether an intensive follow-up program can improve bowel control and quality of life for people who have had rectal cancer surgery. About 140 adults who had surgery and a temporary colostomy will be split into two groups: one gets the intensive program with extra…

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This phase 2 trial tests whether a vaginal DHEA suppository can safely improve vaginal health in 25 women who had radiation for gynecologic, anal, or rectal cancer. Radiation often causes dryness, burning, and pain, similar to menopause. DHEA is a hormone replacement that may hel…

This study compares a bowel management program that includes a retrograde rectal enema (RRE) against standard medical care (fiber, loperamide, pelvic floor therapy) for people with low anterior resection syndrome (LARS) after rectal cancer surgery. Researchers will enroll 80 adul…

This study tests whether a special dressing (Mepilex Lite) placed inside the anal canal, combined with a pain-relieving suppository (indomethacin), can better treat acute radiation dermatitis—painful, red, or ulcerated skin—caused by radiotherapy for rectal cancer. About 274 adul…

This study tests whether online interactive videos that guide core muscle exercises can improve bowel symptoms, psychological distress, and quality of life in people who have had rectal cancer surgery. About 110 adults with stage I-III rectal cancer will be assigned to either a g…

This study tests a shorter course of radiation (39 Gy in 13 sessions) to relieve symptoms like bleeding and pain in 50 adults with rectal cancer who cannot have surgery due to age, other illnesses, or cancer spread. The goal is to see if this approach improves comfort and quality…

This study explores whether acupuncture can reduce nerve pain and numbness caused by chemotherapy in people with gynecologic, urologic, or rectal cancers. About 75 participants will be randomly assigned to receive real acupuncture, sham acupuncture, or usual care for 6 weeks. The…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study tests a program called CARES that provides nurse navigators and counselors to rural cancer patients. The goal is to see if this support helps patients start and finish treatment more quickly and improves their quality of care. About 320 adults with solid tumors like lu…

This study compares two surgical methods (Parks and Bacon) for ultra-low rectal cancer to see which one leads to better bowel function and quality of life a year after surgery. About 256 adults with rectal cancer will take part. The goal is to help doctors choose the best techniq…

This study tests a device that maps pelvic nerves during rectal cancer surgery. The goal is to help surgeons avoid damaging nerves that control bladder, bowel, and sexual function. About 44 adults with rectal cancer will be monitored during surgery and followed for three months t…

This study looks at whether people with rectal cancer can stick to a ketogenic diet (very low carbs, high fat) during chemoradiation. About 194 participants will be randomly assigned to either the ketogenic diet or a standard Mediterranean diet for 5 weeks. The main goal is to se…

This study looks at whether a simple blood test can help doctors decide if rectal cancer patients can avoid surgery and keep their rectum. Researchers will measure tiny bits of tumor DNA in the blood (ctDNA) before, during, and after standard treatment. The goal is to see if chan…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study looks at whether preserving the left colic artery during colon or rectal cancer surgery helps keep the remaining colon well-supplied with blood. Surgeons will temporarily clamp the main artery and use a green dye to measure blood flow. The goal is to see if this techni…

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to cancer treatment can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online …

This study looks at whether having a healthcare provider directly contact close relatives of people with newly diagnosed colorectal cancer leads to more genetic testing than having the patient share the information themselves. About 4,186 patients and their relatives will take pa…

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study follows 430 people with stage I-IV rectal cancer to measure their quality of life after surgery. Participants fill out questionnaires about their well-being and daily function. The goal is to learn how surgery impacts patients over time, not to test a new treatment.

This first-in-human study tests a machine learning system that provides real-time guidance during robot-assisted rectal cancer surgery. The system aims to help surgeons by predicting the correct surgical plane. Twelve patients with rectal cancer will be enrolled to see if the tec…

This study aims to find biomarkers in tumor tissue that can predict whether a patient with locally advanced rectal cancer will resist neoadjuvant chemoradiotherapy. About half of patients do not respond well to this treatment, and identifying these patients beforehand could help …

This trial tests whether a new type of MRI, called hyperpolarized carbon-13 MRI, can better predict how rectal cancer responds to chemoradiotherapy. By tracking how cancer cells use energy, along with blood and tissue analysis, researchers hope to identify complete tumor response…

This study looks at how letting cancer patients choose which genetic results they receive affects their understanding, expectations, and satisfaction. Adults with certain cancers (cholangiocarcinoma, multiple myeloma, or early-onset colon or rectal cancer) can join. Participants …

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study is testing whether special PET-MRI scans can predict how well rectal cancer responds to chemotherapy and radiation before surgery. Researchers will scan 50 patients multiple times during treatment to see if early changes in the tumor can forecast the final outcome. The…

This study is looking at how short-course radiation therapy (5 days of treatment) affects the immune system in people with rectal cancer. Researchers will collect blood, stool, and tumor tissue samples before, during, and after radiation to study these changes. The goal is to bet…

This study looks at whether the types of bacteria in the gut and surrounding tissues can help predict how rectal cancer will progress. Researchers will collect stool, tissue, and fat samples from 100 people with rectal cancer and compare them to healthy controls. The goal is to f…

This study aims to learn more about how the body responds to standard treatments for rectal cancer, including chemoradiation and chemotherapy. Researchers will analyze participants' blood, tissue, and scans to see if these tests can predict whether the cancer improves, worsens, o…

This study is building a smart model that uses scans, gut bacteria, and blood tests to see if rectal cancer patients can safely avoid surgery after initial treatment. Researchers will follow 869 patients to find out who can use a 'watch-and-wait' approach instead of an operation.…

This study looks at 200 adults with rectal cancer who had chemoradiotherapy and then chose organ-preserving treatment. Some had a small local surgery to remove the scar, while others did not. Researchers will compare bowel, bladder, and sexual function between the two groups over…

This study looks at tiny particles called exosomes in the blood of 30 adults with rectal cancer who are getting chemotherapy and radiation before surgery. The goal is to see if changes in these particles can predict how well the tumor responds to treatment. This is an observation…

This study is gathering blood and tumor samples from 1,200 people with colorectal cancer who are having surgery to remove their cancer. Researchers want to look for biomarkers that might help predict how well patients do after surgery. The study does not test a new treatment, but…

This international study aims to understand why colorectal cancer is becoming more common in people under 50. Researchers will compare the diet, lifestyle, and medical history of 2,300 participants—half with early-onset colorectal cancer and half healthy volunteers. The goal is t…

This study is testing a new blood test that looks for tiny bits of cancer DNA to see if it can predict how well treatment works for people with advanced rectal cancer. Researchers will collect blood and tissue samples from 60 patients before, during, and after treatment. The goal…

This study is testing whether an artificial intelligence (AI) system can analyze MRI scans to predict how well rectal cancer responds to chemotherapy and radiation before surgery. Researchers will enroll 1,700 adults with locally advanced rectal cancer. The goal is to help doctor…

This study aims to improve how doctors tell the difference between real tumor growth and pseudoprogression (a harmless, temporary increase in tumor size) after immunotherapy for rectal cancer. Researchers will use multiple MRI scans and blood tests from 300 participants to build …

This study is collecting blood, urine, tissue, and stool samples from 250 people with locally advanced rectal cancer who are about to receive chemotherapy and radiation before surgery. Researchers will analyze these samples for tiny substances called metabolites to see if they ca…

This study is collecting information from up to 999 people with rectal cancer who are treated with a special device called the MAASTRO HDR applicator. The goal is to learn how well it works and what side effects it causes, so doctors can improve future treatments. Participants wi…

This study is creating and testing a mobile health app designed to help colorectal cancer survivors and their family caregivers follow healthy lifestyle recommendations. Researchers will work with 70 participants to see if the app is easy to use and acceptable. The goal is to imp…

This study is collecting stool and saliva samples from 2,500 people with colorectal cancer to look for patterns in bacteria and genetic material (microRNA). The goal is to improve how doctors diagnose and predict the course of the disease. Participants provide samples at key poin…

This study looks at how Y90 radioembolization, a radiation treatment for liver tumors that have spread from colorectal cancer, actually works inside the body. Researchers will collect small tissue samples (biopsies) from the liver after treatment to see how much tumor damage occu…

This study is a large registry that will follow about 8,000 cancer patients who receive radiation therapy using a special machine called an MR-Linac, which combines an MRI scanner with a radiation beam. The goal is to learn how well this technology works for different cancers, in…

This study follows 368 colorectal cancer survivors aged 25 to 65 to see how their quality of life changes 6, 12, and 24 months after treatment. Researchers will use questionnaires to measure physical, mental, and social well-being and look for late side effects linked to specific…

This study looks at whether a special type of MRI, called amide proton transfer-weighted imaging, can accurately predict if rectal cancer has completely disappeared after chemotherapy and radiation. Researchers will compare the MRI results with the actual tissue removed during su…

This study follows 150 rectal cancer patients to understand why some have long-term bowel problems after treatment. Participants use a smartphone app to track symptoms and fill out quality-of-life questionnaires. The goal is to create personalized care plans that address each pat…

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This study follows 100 adults with rectal cancer for 2 years after surgery to see how bowel function changes over time. Researchers will compare different treatment plans to find out which ones lead to better bowel control and quality of life. The goal is to help doctors and pati…

This study looks at gut bacteria in 300 people with colorectal cancer to see if certain bacteria are linked to cancer spread. Researchers will compare stool and tissue samples from patients whose cancer has spread versus those whose cancer has not. The goal is to find bacterial p…

This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the …

This study looks at whether a pre-surgery program of exercise and nutrition advice is practical for people with stage II or III rectal cancer. About 40 participants will either join the program or receive usual care. The main goal is to see if enough people sign up and stick with…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This clinical trial is looking at how chemoradiation given before surgery affects circulating tumor cells (CTCs) in patients with stage II-III rectal cancer. CTCs are cancer cells that travel in the blood and may indicate how likely the cancer is to spread. The study will compare…